BESPONSA under the microscope: korean study tracks Real-World safety
NCT ID NCT04307134
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study monitored the safety and effectiveness of BESPONSA (inotuzumab ozogamicin) in 108 Korean adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug is already approved in Korea, and this post-marketing surveillance was required to check for any problems in everyday use. Researchers tracked side effects and how well the drug worked, focusing on serious events like liver damage (VOD/SOS).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inotuzumab ozogamicin (BESPONSA)
What this could lead to
If results confirm its safety profile, it supports BESPONSA as a treatment option for relapsed/refractory B-cell ALL in routine practice.
What could go wrong
This is a post-marketing surveillance study, not a new clinical trial. It mainly tracks known side effects like liver problems (VOD/SOS) and does not test a new approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea